Europe Molecular Diagnostics Market Size, Share & Trends Analysis Report and Segment Forecast, 2024| Grand View Research, Inc “The Europe molecular diagnostics market size was valued at USD 1,750.0 million in 2015 and is expected to exhibit attractive growth over the forecast period.” The Europe Molecular Diagnostics Market is expected to reach USD4.0 billion by 2024, according to a new report by Grand View Research, Inc. Growing geriatric population and the increasing prevalence of neurological and cardiovascular disorders is expected to drive the growth of molecular diagnostics. Moreover, increasing demand for more efficient healthcare delivery to facilitate early diagnostics is further expected to boost market growth. Rising awareness levels among individuals pertaining to the availabili ty of effective molecular diagnostic tests to determine the presence of genetic disorders is expected to increase the client base for this industry, consequently leading to early diagnosis of disorders in the population. In addition, with the demand for high levels of accuracy and cost effectiveness of diagnostic procedures, the existent technologies are continually undergoing progressive changes to develop improved and efficient testing tools. Presence of a number of established healthcare facilities coupled with the technological advancements facilitating and expediting accurate disease diagnosis are expected to serve this market as significant drivers fueling growth. To request a sample copy or view summary of this report, click the link below: http://www.grandviewresearch.com/industry-analysis/europe-molecular-diagnosti cs-market Further key findings from the study suggest: Follow Us: The overall vertical was dominated by the reagents with their revenue generation estimated at over USD 930.0 million in 2015 owing to their higher usage including formamide, salts, an d dextran sulphate or heparin employed in the drug development process to detect disease -related novel biomarkers Introduction of reagents for technologically advanced instruments are anticipated to attribute towards an attractive growth of reagents segment over the forecast period Central laboratories held the largest market share of around 60% in 2015 owing to the h ighly developed healthcare infrastructure and skilled healthcare professionals & staff associated with them. Point of care is the fastest growing test location segment with an estimated CAGR of over 12.0% over the forecast period. Increasing demand for expedited diagnosis and rapid analysis has led to the growth of this section. Infectious diseases dominated the market on the basis of application with the largest revenue contribution in 2015 owing to the large test volumes and extensive portfolio of commercialized products in this area. HIV held the largest market share of around 14.0% in 2015 in the infectious disease segment. Government initiatives being undertaken in Italy and France to create higher awareness about infectious diseases, such as HIV/AIDS and Hepatitis B, are factors responsible for its high market share. Polymerase chain reaction (PCR) technology dominated the vertical with overall market revenue of over USD 725.0 million, attributable to the increasing application of molecular diagnostics in the field of drug discovery & development and pharmacogenomi cs DNA sequencing is estimated to emerge as a profitable market over the forecast period with a CAGR of around 15.0%. With the sweeping technological advancements in the field, DNA sequencing i s presently one of the most cost-effective technologies used to decode the genetic cause underlying a range of diseases. The next generation sequencing technology segment will witness the highest growth rate throughout the forecast period majorly owing to the increasing R&D initiatives for development of novel drugs. Germany held the largest market share with maximum revenue generation in 2015, which is attributed primarily to its huge elderly population base. Growing geriatric population coupled with decre ased immune levels would engender the widespread prevalence of chronic diseases conditions comprising cardiovascular, neurological, and diabetes The molecular diagnostics sector in the UK is estimated to grow at a faster rate with a CAGR of over 11.0% throughout the forecast period. The presence of sophisticated healthcare infrastructure, higher disposable income, and the increasing R&D intensity are the key factors contributing towards the growth of this sector in the UK. Follow Us: Some leading companies in the molecular diagnostics sector include Roche Diagnostics, Alere Inc., Cepheid, Hologic, Inc. (Gen Probe), Sysmex Corporation, Abbott Laboratories, Bayer AG, Siemens Healthcare GmbH, Becton, Dickinson and Company, Johnson & Johnson, bioMérieux SA, Dako, Novartis AG (Grifols), Danaher Corporation, Bio-Rad Laboratories, Inc., and Qiagen N.V. The established players in this vertical are adopting strategies, such as mergers and acquisitions, new product development, expansion activities pertaining to R&D of novel diagnostic products, and strategic collaborations to widen their existent product portfolios Grand View Research has segmented the Europe molecular diagnostics market on the basis of product, technology, applications, test location, and country: Europe Molecular Diagnostics Product Outlook (Market Revenue in USD Million, 2013 - 2024) Instruments Reagents Others Europe Molecular Diagnostics Test Location Outlook (Market Revenue in USD Million, 2013 - 2024) Point of care Self-testing or OTC Central laboratories Europe Molecular Diagnostics Technology Outlook (Market Revenue in USD Million, 2013 - 2024) PCR In-situ hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Chips and microarrays Mass spectrometry Sequencing Transcription-mediated amplification Others Europe Molecular Diagnostics PCR, by segments Outlook (Market Revenue in USD Million, 2013 - 2024) Follow Us: Multiplex PCR Others Europe Molecular Diagnostics Application Outlook (Market Revenue in USD Million, 2013 - 2024) Oncology Pharmacogenomics Infectious diseases Genetic testing Neurological diseases Cardiovascular diseases Microbiology Others Europe Molecular Diagnostics Oncology, By Application Outlook (Market Revenue in USD Million, 2013 2024) Breast Cancer Prostate Cancer Colorectal Cancer Cervical Cancer Kidney Cancer Liver Cancer Blood Cancer Lung Cancer Others Europe Molecular Diagnostics Infectious Disease, By Application Outlook (Market Revenue in USD Million, 2013 - 2024) Methicillin-resistant Staphylococcus aureus (MRSA) Clostridium difficile Follow Us: Vancomycin-resistant enterococci Carbapenem-resistant bacteria testing Flu Respiratory syncytial virus (RSV) Candida Tuberculosis and drug-resistant TB Meningitis Gastro-intestinal panel testing Chlamydia Gonorrhea HIV Hepatitis C Hepatitis B Other Europe Molecular Diagnostics Genetic Testing, By Application Outlook (Market Revenue in USD Million, 2013 - 2024) Newborn screening Predictive and presymptomatic testing Others Europe Molecular Diagnostics Country Outlook (Market Revenue in USD Million, 2013 - 2024) UK Germany France Spain Italy Follow Us: Belgium Switzerland Netherlands Poland Austria Greece Sweden Turkey Finland Follow Us: Table of Content of Europe Molecular Diagnostics Market Chapter 1 Executive Summary Chapter 2 Europe Molecular Diagnostics - Industry Outlook 2.1 Introduction 2.2 Market Segmentation 2.3 Market Size and Growth Prospects 2.4 Molecular Diagnostics - Market dynamics 2.4.1 Market Driver Analysis 2.4.1.1 Growing geriatric population base 2.4.1.2 Introduction of technological advancements 2.4.1.3 Increasing demand for point of care facilities 2.4.1.4 Growing prevalence of target diseases such as hospital acquired infections, genetic, and cardiovascular &neurological diseases 2.4.1.5 External funding for executing research and development activities 2.4.2 Market Restraint Analysis 2.4.2.1 Presence of an ambiguous regulatory framework 2.4.2.2 High prices of molecular diagnostic tests 2.5 Key Opportunities Prioritized 2.6 Molecular Diagnostics - PESTEL Analysis 2.7 Molecular Diagnostics Market - Company Market Share Analysis, 2013 2.7.1 Recommendations for market participants Chapter 3 Europe Molecular Diagnostics Product Outlook 3.1 Molecular Diagnostics Revenue Share, by Product, 2013 & 2024 3.2 Molecular Diagnostic Instruments Market 3.2.1 Molecular diagnostic instruments market, 2013 - 2024 (USD Million) 3.3 Molecular Diagnostic Reagents Market 3.3.1 Molecular diagnostic reagents market, 2013 - 2024 (USD Million) 3.4 Others 3.4.1 Other molecular diagnostic products market, 2013 - 2024 (USD Million) Chapter 4 Europe Molecular Diagnostics Test Location Outlook 4.1 Molecular Diagnostics Revenue Share, by Test Location, 2013 & 2024 Follow Us: 4.2 Molecular Diagnostic Point of Care Market 4.2.1 Molecular diagnosticspoint of care market, 2013 - 2024 (USD Million) 4.3 Molecular Diagnostics Self-Test or OTC Market 4.3.1 Self-Test or OTC molecular diagnostics market, 2013 - 2024 (USD Million) 4.4 Molecular Diagnostic Central Laboratories Market 4.4.1 Molecular diagnostic central laboratories market, 2013 - 2024 (USD Million) Chapter 5 Europe Molecular Diagnostics Application Outlook 5.1 Molecular Diagnostics Revenue Share, by Application, 2013 & 2024 5.2 Molecular Diagnostics-based Infectious Diseases Market 5.2.1 Molecular diagnostics-based infectious diseasesmarket, 2013 - 2024 (USD Million) 5.3 Molecular Diagnostics-based Genetic Testing Market 5.3.1 Molecular diagnostics-based genetic testing market, 2013 - 2024 (USD Million) 5.4 Molecular Diagnostics-based Oncology Market 5.4.1 Molecular diagnostics-based oncology market, 2013 - 2024 (USD Million) 5.5 Molecular Diagnostic-based Pharmacogenomics Market 5.5.1 Molecular diagnostics-based Pharmacogenomics market, 2013 - 2024 (USD Million) 5.6 Molecular Diagnostics-based Cardiovascular Diseases Market 5.6.1 Molecular diagnostics-basedcardiovascular diseases market, 2013 - 2024 (USD Million) 5.7 Molecular Diagnostics-based Neurological Diseases Market 5.7.1 Molecular diagnostics-basedneurological diseases market, 2013 - 2024 (USD Million) 5.8 Molecular Diagnostics in Other Application Segments Market 5.8.1 Molecular Diagnostics in other application segments, 2013 - 2024 (USD Million) Chapter 6 Europe Molecular Diagnostics Technology Outlook 6.1 Molecular Diagnostics Revenue Share by Technology, 2013 &2013 & 2024 6.2 Molecular Diagnostics Polymerase Chain Reaction (PCR) Market 6.2.1 Molecular diagnostics PCR Market, 2013 - 2024 (USD Million) 6.2.2 Multiplex PCR-based molecular diagnostics market 6.3 Molecular Diagnostics Transcription-mediated Amplification (TMA) Market 6.3.1 Molecular diagnostics TMA Market, 2013 - 2024 (USD Million) 6.4 Molecular Diagnostics In-situ Hybridization Market 6.4.1 Molecular diagnostic in-situ hybridization market, 2013 - 2024 (USD Million) Follow Us: 6.5 Molecular Diagnostic Sequencing Market 6.5.1 Molecular diagnostic sequencing market, 2013 - 2024 (USD Million) 6.6 Molecular Diagnostics Chips and Microarrays Market 6.6.1 Molecular Diagnostics Chips and Microarrays Market, 2013 - 2024 (USD Million) 6.7 Molecular Diagnostics Mass Spectrometry (MS) Market 6.7.1 Molecular diagnostics MSmarket, 2013 - 2024 (USD Million) 6.8 Molecular Diagnostic Other Technology Segments Market 6.8.1 Molecular diagnostic other technology segments market, 2013 - 2024 (USD Million) Chapter 7 Europe Molecular Diagnostics Regional Outlook 7.1 Europe Molecular Diagnostics Revenue Share by Region, 2013 &2013 & 2024 7.2 UK 7.2.1 UK molecular diagnosticsmarket, 2013 - 2024 (USD Million) 7.3 Germany 7.3.1 Germany molecular diagnostics market, 2013 - 2024 (USD Million) 7.4 France 7.4.1 France molecular diagnostics market, 2013 - 2024 (USD Million) 7.5 Italy 7.5.1 Italy molecular diagnostics market, 2013 - 2024 (USD Million) 7.6 Spain 7.6.1 Spain molecular diagnostics market, 2013 - 2024 (USD Million) 7.7 Belgium 7.7.1 Belgium molecular diagnostics market, 2013 - 2024 (USD Million) 7.8 Switzerland 7.8.1 Switzerland molecular diagnostics market, 2013 - 2024 (USD Million) 7.9 Netherlands 7.9.1 Netherlands molecular diagnostics market, 2013 - 2024 (USD Million) 7.10 Poland 7.10.1 Poland molecular diagnostics market, 2013 - 2024 (USD Million) 7.11 Austria 7.11.1 Austria molecular diagnostics market, 2013 - 2024 (USD Million) 7.12 Greece Follow Us: 7.12.1 Greece molecular diagnostics market, 2013 - 2024 (USD Million) 7.13 Sweden 7.13.1 Sweden molecular diagnostics market, 2013 - 2024 (USD Million) 7.14 Turkey 7.14.1 Turkey molecular diagnostics market, 2013 - 2024 (USD Million) 7.15 Finland 7.15.1 Finland molecular diagnostics market, 2013 - 2024 (USD Million) Chapter 8 Competitive Landscape 8.1 Abbott Laboratories 8.1.1 Company overview 8.1.2 Financial performance 8.1.3 Product benchmarking 8.1.4 Strategic initiatives 8.2 Alere, Inc. 8.2.1 Company overview 8.2.2 Financial performance 8.2.3 Product benchmarking 8.2.4 Strategic initiatives 8.3 Bayer Healthcare 8.3.1 Company overview 8.3.2 Financial performance 8.3.3 Product benchmarking 8.3.4 Strategic initiatives 8.4 Becton, Dickinson and Company 8.4.1 Company overview 8.4.2 Financial performance 8.4.3 Product benchmarking 8.4.4 Strategic initiatives 8.5 bioMerieux 8.5.1 Company overview 8.5.2 Financial performance Follow Us: 8.5.3 Product benchmarking 8.5.4 Strategic initiatives 8.6 Bio-Rad Laboratories, Inc. 8.6.1 Company overview 8.6.2 Financial performance 8.6.3 Product benchmarking 8.6.4 Strategic initiatives 8.7 Cepheid 8.7.1 Company overview 8.7.2 Financial performance 8.7.3 Product benchmarking 8.7.4 Strategic initiatives 8.8 Dako 8.8.1 Company overview 8.8.2 Financial performance 8.8.3 Product benchmarking 8.8.4 Strategic initiatives 8.9 Danaher Corporation 8.9.1 Company overview 8.9.2 Financial performance 8.9.3 Product benchmarking 8.9.4 Strategic initiatives 8.10 Hologic, Inc. (Gen Probe) 8.10.1 Company overview 8.10.2 Financial performance 8.10.3 Product benchmarking 8.10.4 Strategic initiatives 8.11 Johnson & Johnson 8.11.1 Company overview 8.11.2 Financial performance 8.11.3 Product benchmarking Follow Us: 8.11.4 Strategic initiatives 8.12 Novartis AG (Grifols) 8.12.1 Company overview 8.12.2 Financial performance 8.12.3 Product benchmarking 8.12.4 Strategic initiatives 8.13 Qiagen N.V. 8.13.1 Company overview 8.13.2 Financial performance 8.13.3 Product benchmarking 8.13.4 Strategic initiatives 8.14 Roche Diagnostics 8.14.1 Company overview 8.14.2 Financial performance 8.14.3 Product benchmarking 8.14.4 Strategic initiatives 8.15 Siemens Healthcare GmbH 8.15.1 Company overview 8.15.2 Financial performance 8.15.3 Product benchmarking 8.15.4 Strategic initiatives 8.16 Sysmex Corporation 8.16.1 Company overview 8.16.2 Financial performance 8.16.3 Product benchmarking 8.16.4 Strategic initiatives Chapter 9 Methodology and Scope 9.1 Research Methodology 9.2 Research Scope & Assumptions 9.3 List of Data Sources Follow Us: About Us: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: [email protected] For More Information: https://www.grandviewresearch.com Blog: https://healthcareforecastreport.blogspot.com/ Follow Us:
The europe molecular diagnostics market is expected to reach USD4.0 billion by 2024
© Copyright 2024 Paperzz
